Clinical Trials Logo

Stage IV Pancreatic Cancer clinical trials

View clinical trials related to Stage IV Pancreatic Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05240690 Not yet recruiting - Clinical trials for Stage IV Pancreatic Cancer

Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies

Start date: February 7, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.And to investigate the initial efficacy of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.

NCT ID: NCT04377048 Not yet recruiting - Clinical trials for Stage IV Pancreatic Cancer

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

This study assumes that to achieve significant therapeutic efficacy in advanced pancreatic cancer with immunotherapy, the immune system must remain relatively intact. Therefore, early use, low tumor load, adequate organ function, and slow growth of the tumor are the key points. Stage IV pancreatic adenocarcinoma patients with limited metastatic lesions and adequate organ function will be enrolled. Gemcitabine plus S-1 (GS) will be administered initially, and then CA 19-9 will be evaluated. Those fulfilling pre-defined criteria of CA 19-9 will receive nivolumab add-on therapy.